VivoSeq
Other

Richter Syndrome

9

Pipeline Programs↗

2

Active Trials↗

6

Companies Involved↗

Richter syndrome is an early-stage landscape with 9 programs across 6 companies. The most active players are Roche, Merck & Co., Bristol-Myers Squibb. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

0/100

Mech. Concentration

22/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

3 programs

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2K

Karyopharm Therapeutics Inc

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2AbbVie logo

AbbVie

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

70%

Monoclonal antibody

7 of 10 classified programs — the dominant modality here.

30%ALL OTHERSSmall molecule330%

Monoclonal antibody leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 100% of 10 pipeline programs.

Analysis

Trial Status

3

clinical trials

Completed1 · 33%
Active, not recruiting1 · 33%
Recruiting1 · 33%

Clinical Trials

Trial Activity

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT02576990·80 enrolled
Venetoclax Plus Dose-adjusted R-EPOCH or R-CHOP for Richter's Syndrome
Active, not recruiting·DDana-Farber Cancer Institute·Phase 2·NCT03054896·69 enrolled
A Phase 2 Study Evaluating the Bispecific CD3xCD20 Antibody GLOfitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) in Patients With RIchter Syndrome as Frontline therapY. A FILO Study
Recruiting·FFrench Innovative Leukemia Organisation·Phase 2·NCT06186648·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)